Celerus Diagnostics Taps Douglas Sweet to Head Marketing and Sales; Pathology Industry Veteran Brings Extensive Experience to Growing Startup.

SANTA BARBARA, Calif. -- Celerus Diagnostics, Inc., the cancer diagnostics company focused on rapid tumor testing, today announced the addition of industry veteran Douglas Sweet to their management team.

Responsible for sales and marketing management at diagnostics companies such as DAKO, BioPath and Ventana Medical Systems, Mr. Sweet has over 30 years experience in the field of pathology. He has held senior positions in sales and marketing at Molecular Devices, Syva (diagnostic division of Syntex), New England Nuclear and Corning Medical. Most recently, he has been an advisor to several private entrepreneurial companies preparing to enter the Diagnostics Industry with products resulting from the Human Genome Project.

"Doug has a proven track record in both start-up environments and established companies," said Michael Sarrasin, Chief Operating Officer of Celerus Diagnostics. "Not only will he provide a high level of leadership, his expertise and knowledge of the market will further expand our product offerings and contribute significantly to the growth of Celerus."

With extensive experience in relationship building in the diagnostic market, Mr. Sweet's strategic planning and vision has led to the successful launch of over 14 instrument and reagent systems into the IVD marketplace.

"Celerus has developed incredibly unique technologies that expand the testing capabilities and responsiveness of the pathology laboratory," said Mr. Sweet. "I am extremely pleased to join a team of experienced professionals dedicated to building products of the highest quality and providing the greatest laboratory efficiency."

Mr. Sarrasin continued, "I believe Doug's addition to the team will establish Celerus Diagnostics as a significant worldwide competitor in the anatomic pathology marketplace."

Mr. Sweet holds a BS in Biology from the University of Oregon and an MBA from the Presidential/Key Executive program at Pepperdine University.

About Celerus:

Founded in 2004 in Santa Barbara, California, Celerus Diagnostics is committed to enhancing the diagnostic capabilities of the pathology laboratory. Celerus technology provides the capability to decentralize testing, and move results closer to the patient for real time decision making. For more information, please visit our website: www.celerusdiagnostics.com or contact us at 805-685-0797.

This release contains forward-looking statements that involve risks and uncertainties, including, but not limited to, Celerus Diagnostics' ability to successfully complete its development program, competitive pressures and other factors such as the introduction or regulatory approval of new products by our competitors and pricing of competing products and the resulting effects on sales and pricing of our products, disruptions or other problems with our sources of supply, significant product liability or other claims, difficulties with new product development and market acceptance, changes in the mix of our products sold, patent conflicts, product recalls, United States Food and Drug Administration (FDA) delay in or approval or rejection of new or existing products, changes in Medicare, Medicaid or third-party reimbursement policies, changes in government regulation, use of hazardous or environmentally sensitive materials, our inability to implement new information technology systems, our inability to integrate new acquisitions, and other events. This press release reflects information as of the date of this press release, and the company takes no responsibility in updating the information contained herein now or in the future.